Terms: = Liver cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
1057 results:
1. Robotic sectionectomy versus robotic hemihepatectomy for anatomic liver resection: a comparative analysis of perioperative outcomes.
Birgin E; Heibel M; Téoule P; Reißfelder C; Rahbari NN
J Robot Surg; 2024 May; 18(1):197. PubMed ID: 38703346
[TBL] [Abstract] [Full Text] [Related]
2. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract] [Full Text] [Related]
3. The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis).
Taghizadeh M; Jafari-Koshki T; Jafarlou V; Raeisi M; Alizadeh L; Roosta Y; Matin S; Jabari R; Sur D; Karimi A
BMC Cancer; 2024 Apr; 24(1):484. PubMed ID: 38627675
[TBL] [Abstract] [Full Text] [Related]
4. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
5. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract] [Full Text] [Related]
6. Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: The Effectiveness of Different Particle Sizes in Downstaging and Bridging in Living Donor liver Transplantation.
Lim WX; Sim KS; Chen CL; Ou HY; Yu CY; Cheng YF
Transplant Proc; 2024 Apr; 56(3):596-601. PubMed ID: 38472083
[TBL] [Abstract] [Full Text] [Related]
7. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.
Hsiehchen D; Beg MS; Kainthla R; Lohrey J; Kazmi SM; Khosama L; Maxwell MC; Kline H; Katz C; Hassan A; Kubota N; Siglinsky E; Pillai AK; Youssoufian H; Mockbee C; Culm K; Uhlik M; Benjamin L; Brekken RA; Ahn C; Singal AG; Zhu H; Hoshida Y; Yopp AC
Nat Commun; 2024 Mar; 15(1):2178. PubMed ID: 38467639
[TBL] [Abstract] [Full Text] [Related]
8. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract] [Full Text] [Related]
9. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract cancer: An Exploratory Analysis of Real-World Data.
Olkus A; Tomczak A; Berger AK; Rauber C; Puchas P; Wehling C; Longerich T; Mehrabi A; Chang DH; Liermann J; Schäfer S; Pfeiffenberger J; Jäger D; Michl P; Springfeld C; Dill MT
Target Oncol; 2024 Mar; 19(2):213-221. PubMed ID: 38416377
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis.
Dawood ZS; Brown ZJ; Alaimo L; Lima HA; Shaikh C; Katayama ES; Munir MM; Moazzam Z; Endo Y; Woldesenbet S; Pawlik TM
HPB (Oxford); 2024 May; 26(5):618-629. PubMed ID: 38369433
[TBL] [Abstract] [Full Text] [Related]
11. Development of a short-term nutritional risk prediction model for hepatocellular carcinoma patients: a retrospective cohort study.
Yu J; Lam SK; He L; Wang P; Cao Y
Sci Rep; 2024 Feb; 14(1):3921. PubMed ID: 38365922
[TBL] [Abstract] [Full Text] [Related]
12. Activity of Tepotinib in Hepatocellular Carcinoma With High-Level
Qin S; Pan H; Blanc JF; Grando V; Lim HY; Chang XY; O'Brate A; Stroh C; Friese-Hamim M; Albers J; Johne A; Faivre S
JCO Precis Oncol; 2024 Feb; 8():e2300328. PubMed ID: 38354329
[TBL] [Abstract] [Full Text] [Related]
13. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract] [Full Text] [Related]
14. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series.
Sia TY; Wan V; Finlan M; Zhou QC; Iasonos A; Zivanovic O; Sonoda Y; Chi DS; Long Roche K; Jewell E; Tew WP; O'Cearbhaill RE; Cohen S; Makker V; Liu YL; Friedman CF; Kyi C; Zamarin D; Gardner G
Int J Gynecol Cancer; 2024 Apr; 34(4):594-601. PubMed ID: 38296517
[TBL] [Abstract] [Full Text] [Related]
15. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
[TBL] [Abstract] [Full Text] [Related]
16. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of 2-Substituted Aniline Pyrimidine Derivatives as Potent Dual Mer/c-met Inhibitors.
Huang D; Chen Y; Yang J; Zhao B; Wang S; Chai T; Cui J; Zhou X; Shang Z
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257391
[TBL] [Abstract] [Full Text] [Related]
18. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
19. Clinical Characteristics, treatment Patterns, and Outcomes of Patients With Locally Advanced/metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration.
Alkadimi MA; Aldawoodi TA; Lucero KT; Fierro ME; Boyle LD; Mader MJ; Franklin KR; Arora SP; Nooruddin Z
Oncologist; 2024 May; 29(5):369-376. PubMed ID: 38254242
[TBL] [Abstract] [Full Text] [Related]
20. Anti-hepatocellular carcinoma activity of Sorbaria sorbifolia by regulating VEGFR and c-met/apoptotic pathway.
Xu ZH; Dang Y; Dong Y; Dong CY; Liu Y; Chen X; Yao Z; Shi JP
J Ethnopharmacol; 2024 Apr; 324():117758. PubMed ID: 38246481
[TBL] [Abstract] [Full Text] [Related]
[Next]
